Study to Assess Safety Tolerability Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies

  • End date
    Mar 2, 2022
  • participants needed
  • sponsor
Updated on 27 October 2021
renal function
chronic lymphocytic leukemia
multiple myeloma
hodgkin's disease
chronic myelomonocytic leukemia
secondary aml
lymphocytic leukemia
secondary acute myeloid leukemia
progressive disease
richter syndrome


The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity of AZD4573 in subjects with relapsed or refractory haematological malignancies.

Condition childhood ALL, Chronic myelomonocytic leukemia, Multiple Myeloma, Juvenile Myelomonocytic Leukemia, Acute myeloid leukemia, Lymphoproliferative Disorder, Chronic Lymphocytic Leukemia, B-Cell Lymphoma, T-Cell Lymphoma, Lymphocytic Leukemia, Chronic, Lymphoma, B-Cell, Acute Myelogenous Leukemia (AML), Richter Syndrome, High Risk Myelodysplastic Syndrome, Lymphocytic Leukemia, Acute, Relapsed or Refractory Haematological Malignancies Including, Richter's Syndrome, Richter's Transformation, Lymphoproliferative disorders, leukemia, acute lymphoblastic, leukemia chronic lymphocytic, chronic lymphocytic leukemia (cll), small lymphocytic lymphoma, b-cell small lymphocytic lymphoma, multiple myeloma (mm), acute lymphoid leukaemia, acute lymphocytic leukemia, acute lymphoblastic leukemia (all), acute myelogenous leukemia, anll, acute myeloblastic leukemia, chronic myelomonocytic leukaemia, cmml
Treatment AZD4573
Clinical Study IdentifierNCT03263637
Last Modified on27 October 2021

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note